References
1. Yung M, James A, Merkus P, et al. International Otology Outcome Group
and the International Consensus on the Categorization of Tympanomastoid
Surgery. J Int Adv Otol 2018;14 (2):216-26 doi:
10.5152/iao.2018.5553[published Online First: Epub Date]|.
2. Kurien G, Greeff K, Gomaa N, Ho A. Mastoidectomy and mastoid
obliteration with autologous bone graft: a quality of life study. J
Otolaryngol Head Neck Surg 2013;42 :49 doi:
10.1186/1916-0216-42-49[published Online First: Epub
Date]|.
3. Yung M, Bennett A. Use of mastoid obliteration techniques in
cholesteatoma. Curr Opin Otolaryngol Head Neck Surg
2013;21 (5):455-60 doi: 10.1097/MOO.0b013e3283646521[published
Online First: Epub Date]|.
4. Trinidade A, Skingsley A, Yung MW. Pediatric cholesteatoma surgery
using a single-staged canal wall down approach: results of a 5-year
longitudinal study. Otol Neurotol 2015;36 (1):82-5 doi:
10.1097/MAO.0000000000000598[published Online First: Epub
Date]|.
5. Valimaki VV, Aro HT. Molecular basis for action of bioactive glasses
as bone graft substitute. Scand J Surg 2006;95 (2):95-102 doi:
10.1177/145749690609500204[published Online First: Epub
Date]|.
6. Drago L, De Vecchi E, Bortolin M, Toscano M, Mattina R, Romano CL.
Antimicrobial activity and resistance selection of different bioglass
S53P4 formulations against multidrug resistant strains. Future Microbiol
2015;10 (8):1293-9 doi: 10.2217/FMB.15.57[published Online
First: Epub Date]|.
7. Lepparanta O, Vaahtio M, Peltola T, et al. Antibacterial effect of
bioactive glasses on clinically important anaerobic bacteria in vitro. J
Mater Sci Mater Med 2008;19 (2):547-51 doi:
10.1007/s10856-007-3018-5[published Online First: Epub
Date]|.
8. Munukka E, Lepparanta O, Korkeamaki M, et al. Bactericidal effects of
bioactive glasses on clinically important aerobic bacteria. J Mater Sci
Mater Med 2008;19 (1):27-32 doi:
10.1007/s10856-007-3143-1[published Online First: Epub
Date]|.
9. Bernardeschi D, Nguyen Y, Russo FY, Mosnier I, Ferrary E, Sterkers O.
Cutaneous and Labyrinthine Tolerance of Bioactive Glass S53P4 in Mastoid
and Epitympanic Obliteration Surgery: Prospective Clinical Study. Biomed
Res Int 2015;2015 :242319 doi: 10.1155/2015/242319[published
Online First: Epub Date]|.
10. Bernardeschi D, Pyatigorskaya N, Russo FY, et al. Anatomical,
functional and quality-of-life results for mastoid and epitympanic
obliteration with bioactive glass s53p4: a prospective clinical study.
Clin Otolaryngol 2017;42 (2):387-96 doi:
10.1111/coa.12748[published Online First: Epub Date]|.
11. Silvola JT. Mastoidectomy cavity obliteration with bioactive glass:
a pilot study. Otolaryngol Head Neck Surg 2012;147 (1):119-26
doi: 10.1177/0194599812438168[published Online First: Epub
Date]|.
12. Merchant SN, Wang P, Jang CH, et al. Efficacy of tympanomastoid
surgery for control of infection in active chronic otitis media.
Laryngoscope 1997;107 (7):872-7 doi:
10.1097/00005537-199707000-00007[published Online First: Epub
Date]|.
13. Saleh HA, Mills RP. Classification and staging of cholesteatoma.
Clin Otolaryngol Allied Sci 1999;24 (4):355-9 doi:
10.1046/j.1365-2273.1999.00272.x[published Online First: Epub
Date]|.